Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is a strong performing precision medicine company with a wide range of testing services and products focused on the transplant patient journey. Their recent acquisition and sale of businesses are expected to positively impact revenue, and they have a strong pipeline of potential products in development. Their recent financial performance has been strong, and the company is confident in its ability to continue growing and gaining market share in the coming years.

Bears say

CareDx is poised for strong and continued growth, with a 50% increase in sales force and improved RCM initiatives leading to increased volumes. The company has established long-term targets for revenue, GM, and EBITDA margin that exceed analyst expectations. With potential adoption of AlloSure Kidney, AlloMap Heart, and the upcoming launch of AlloHeme targeting a $1B TAM and investments in Epic integration, CDNA is making strategic moves to expand its presence in the precision medicine market. However, clinicians and healthcare administrators may be slow to adopt new products, and CDNA's aggressiveness in acquisitions may impact its stock price.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Jun 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.